IE
CHRS icon

Israel Englander’s Coherus Oncology CHRS Stock Holding History

Israel Englander’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-104,200
Closed -$1.46M – 3935
2018
Q2 		$1.46M Buy
+104,200
New +$1.49M ﹤0.01% 2615
2016
Q4 		– Sell
-100,000
Closed -$2.68M – 3367
2016
Q3 		$2.68M Buy
+100,000
New +$2.73M ﹤0.01% 1747
2015
Q4 		– Sell
-50,000
Closed -$1M – 3445
2015
Q3 		$1M Buy
+50,000
New +$1.52M ﹤0.01% 2282

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Israel Englander's CHRS Position: Q2 2026 in Review

Israel Englander reduced its Coherus Oncology (CHRS) stake by 93% in Q2 2026, selling an estimated $475K and leaving 20,749 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #5661.

Israel Englander first reported a position in CHRS in Q1 2015 and has held it in 39 quarters since. The position peaked at $27M in Q3 2016. 145 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Israel Englander held 20,749 shares of Coherus Oncology worth $29K as of Q2 2026.
  • Israel Englander sold 291,237 Coherus Oncology shares in Q2 2026, an estimated $475K.
  • Coherus Oncology made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5661 holding.
  • Israel Englander first reported a position in Coherus Oncology in Q1 2015 and has held it in 39 quarters since.
  • Israel Englander's Coherus Oncology position peaked at $27M in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.